Altimmune (NASDAQ:ALT) is in a good place right now, especially when you consider that the one drug it has in its pipeline is ...
There is considerable potential because it represents an enormous use case ... with 1.2 mg, 1.8 mg, and 2.4 mg doses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback